our pipeline
Yaara Porat
Director, Preclinical Collaboration
The science of Tumor Treating Fields has potential across a broad spectrum of solid tumors. Tumor Treating Fields have shown a consistent anti-mitotic effect in our preclinical and clinical research spanning more than two decades.
We believe we have gained a deep understanding of the underlying mechanism of action and the multiple pathways through which Tumor Treating Fields exert their effects within dividing cancer cells. Our research shows that Tumor Treating Fields can have an anti-mitotic effect in more than 15 different solid tumor types in culture and in several in vivo tumor models, including some of the most aggressive forms of cancer. We are committed to advancing the science of Tumor Treating Fields across a broad spectrum of solid tumors and bringing our therapy to cancer patients who may benefit.
Novocure clinical development milestones
as of January 2025
We also have pre-clinical data for Tumor Treating Fields in these areas:
PRE-CLINICAL
breast cancer
colorectal carcinoma
fibrous histiocytoma
malignant melanoma
meningioma
renal adenocarcinoma
urinary transitional cell carcinoma
cervical cancer
ependymoma
gliosarcoma
medulloblastoma
osteosarcoma
small cell lung cancer
uveal melanoma
clinical trials
We continue to test Tumor Treating Fields as a treatment for a broad range of solid tumors.
We sponsor clinical trials of Tumor Treating Fields in several cancer types. For more information on our ongoing clinical trials, visit novocuretrials.com and clinicaltrials.gov.
additional research
Additional investigator-sponsored trials are also ongoing. For the most up-to-date clinical trial information, including protocol details, please visit the U.S. National Institutes of Health’s website at clinicaltrials.gov.
This information is for medical, and scientific and educational purposes only. Tumor Treating Fields therapy is experimental for the treatment of patients with brain metastases, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Tumor Treating Fields therapy has not been approved by the U.S. Food and Drug Administration for commercial use in these indications. Limited by federal law to investigational use only.